N
Nirupama Sista
Researcher at Durham University
Publications - 15
Citations - 1146
Nirupama Sista is an academic researcher from Durham University. The author has contributed to research in topics: Medicine & Treatment as prevention. The author has an hindex of 9, co-authored 12 publications receiving 504 citations. Previous affiliations of Nirupama Sista include FHI 360.
Papers
More filters
Journal ArticleDOI
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Raphael J. Landovitz,Deborah Donnell,Meredith E. Clement,Brett Hanscom,Leslie Cottle,Lara E. Coelho,Robinson Cabello,Suwat Chariyalertsak,Eileen F. Dunne,Ian Frank,Jorge A Gallardo-Cartagena,Aditya H Gaur,Pedro Gonzales,Ha V Tran,Juan C Hinojosa,Esper G Kallas,Colleen F Kelley,Marcelo H. Losso,J Valdez Madruga,Keren Middelkoop,Nittaya Phanuphak,Breno Santos,Omar Sued,Javier Valencia Huamaní,Edgar T. Overton,Shobha Swaminathan,Carlos del Rio,Roy M. Gulick,Paul G. Richardson,Philip Sullivan,Estelle Piwowar-Manning,Mark A. Marzinke,Craig W. Hendrix,Maoji Li,Zhe Wang,Jeanne M. Marrazzo,Eric S. Daar,Aida Asmelash,Todd T. Brown,Peter J. Anderson,Susan H. Eshleman,Marcus Bryan,Cheryl Blanchette,Jonathan Lucas,Christina Psaros,Steven A. Safren,Jeremy Sugarman,Hyman M. Scott,Joseph J. Eron,Sheldon D. Fields,Nirupama Sista,Kailazarid Gomez-Feliciano,Andrea Jennings,Ryan Kofron,Timothy H. Holtz,Katherine Shin,James F. Rooney,Kimberly Y. Smith,William Spreen,David J. Margolis,Alex R. Rinehart,Adeola Adeyeye,Myron S. Cohen,Marybeth McCauley,Beatriz Grinsztejn,Hptn (PopART) Study Team +65 more
TL;DR: In this paper, safe and effective long-acting injectable agents for preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options for preve...
Journal ArticleDOI
Effect of universal testing and treatment on HIV incidence - HPTN 071 (popart)
Richard J. Hayes,Deborah Donnell,Sian Floyd,Nomtha Mandla,Justin Bwalya,Kalpana Sabapathy,Blia Yang,Mwelwa Phiri,Ab Schaap,Susan H. Eshleman,Estelle Piwowar-Manning,Barry Kosloff,Anelet James,Timothy Skalland,Ethan Wilson,Lynda Emel,David Macleod,Rory Dunbar,Musonda Simwinga,Nozizwe Makola,Virginia Bond,Graeme Hoddinott,Ayana Moore,Sam Griffith,Nirupama Sista,Sten H. Vermund,Wafaa El-Sadr,David N. Burns,James R Hargreaves,Katharina Hauck,Christophe Fraser,Kwame Shanaube,Peter Bock,Nulda Beyers,Helen Ayles,Sarah Fidler,Hptn (PopART) Study Team +36 more
TL;DR: A combination prevention intervention with ART provided according to local guidelines resulted in a 30% lower incidence of HIV infection than standard care and the lack of effect with universal ART was unanticipated and not consistent with the data on viral suppression.
Journal ArticleDOI
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
Lawrence Corey,Peter B. Gilbert,Michal Juraska,David C. Montefiori,Lynn Morris,Shelly Karuna,Srilatha Edupuganti,Nyaradzo Mgodi,Allan C. deCamp,Erika Rudnicki,Yunda Huang,Pedro Gonzales,Robinson Cabello,Catherine Orrell,Javier R. Lama,Fatima Laher,Erica Lazarus,Jorge Sanchez,Ian Frank,Juan C Hinojosa,Magdalena E. Sobieszczyk,Kyle E. Marshall,Pamela G Mukwekwerere,Joseph Makhema,Lindsey R. Baden,James I. Mullins,Carolyn Williamson,John Hural,M. Juliana McElrath,Carter Bentley,Simbarashe Takuva,Margarita M. Gomez Lorenzo,David N. Burns,Nicole Espy,April K. Randhawa,Nidhi Kochar,Estelle Piwowar-Manning,Deborah Donnell,Nirupama Sista,Philip Andrew,James G. Kublin,Glenda Gray,Julie E. Ledgerwood,John R. Mascola,Myron S. Cohen,Hvtn,Hptn,Hptn Study Teams +47 more
TL;DR: VRC01 did not prevent overall HIV-1 acquisition more effectively than placebo, but analyses of VRC01-sensitive HIV- 1 isolates provided proof-of-concept that bnAb prophylaxis can be effective.
Journal ArticleDOI
Preexposure prophylaxis for HIV prevention: where have we been and where are we going?
TL;DR: Questions remain, including how to motivate uptake of and sustain adherence to PrEP for HIV prevention in high-risk populations, how much use is sufficient to achieve HIV protection, and the potential of “next-generation” PrEP agents to improve this effective prevention strategy.
Journal ArticleDOI
Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial
Myron S. Cohen,Ajay Nirula,Mark J. Mulligan,Richard M. Novak,Mary A. Marovich,Catherine Yen,Alexander Stemer,Stockton Mayer,David A. Wohl,Blair Brengle,Brian T. Montague,Ian Frank,Russell J. McCulloh,Carl J. Fichtenbaum,Brad Lipson,Nashwa Gabra,Julio Ramirez,Christine Thai,Wairimu Chege,Margarita M. Gomez Lorenzo,Nirupama Sista,Jennifer Farrior,Meredith E. Clement,Elizabeth R. Brown,Kenneth L. Custer,Jacob Van Naarden,Andrew C. Adams,Andrew E. Schade,Matan C. Dabora,Jack Knorr,Karen L. Price,Janelle Sabo,Jay Tuttle,Paul A. Klekotka,Lei Shen,Daniel Skovronsky +35 more
TL;DR: Bamlanivimab, a neutralizing monoclonal antibody against SARS-CoV-2, may provide rapid protection from SARS infection and COVID-19.